XSHE
301211
, Last price
Name
Hubei Biocause Heilen Pharmaceutical Co Ltd
Chart & performance
P/E
—
P/S
—
EPS
0.08
Vol. 1Y
—
Shs. 5Y
2.95%
Rev. 5Y
-3.46%
Div Yld LY
—
Div Yld TTM
—
Revenues
453m
+1.67%
Net income
35m
-61.87%
CFO
8m
-92.14%
Dividend
Jun 12, 20260.06 /sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Hubei Biocause Heilen Pharmaceutical Co., Ltd. is a Chinese enterprise with diverse operations spanning the pharmaceutical, chemical, and new energy fuel sectors. Within its pharmaceutical segment, the company manufactures active pharmaceutical ingredients (APIs), various intermediates, and finished drug formulations. Furthermore, its chemical offerings include industrial products such as dimethyl ether gas and chloropropionyl chloride. The firm is headquartered in Jingmen, China.
Headquarters & legal address
湖北省荆门高新区·掇刀区杨湾路122号
荆门市, HB 448000
CN
荆门市, HB 448000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||||
Revenues | |||||||||||
Cost of revenue | |||||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | |||||||||||
NOPBT Margin | |||||||||||
Operating Taxes | |||||||||||
Tax Rate | |||||||||||
NOPAT | |||||||||||
Net income | |||||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | |||||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | |||||||||||
Long-term debt | |||||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | |||||||||||
Net debt | |||||||||||
| Cash flow | |||||||||||
Cash from operating activities | |||||||||||
CAPEX | |||||||||||
Cash from investing activities | |||||||||||
Cash from financing activities | |||||||||||
FCF | |||||||||||
| Balance | |||||||||||
Cash | |||||||||||
Long term investments | |||||||||||
Excess cash | |||||||||||
Stockholders' equity | |||||||||||
Invested Capital | |||||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | |||||||||||
Price | |||||||||||
Market cap | |||||||||||
EV | |||||||||||
EBITDA | |||||||||||
EV/EBITDA | |||||||||||
Interest | |||||||||||
Interest/NOPBT | |||||||||||